# Talphera, Inc.: overview TLPH · Nasdaq · CIK 1427925 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/tlph.md) · [Financials](/companies/tlph/financials.md) · [Filings](/companies/tlph/filings.md) · [Insiders](/companies/tlph/insiders.md) Latest reported revenue: [$0](/filings/0001437749-26-027316.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 12, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001437749-26-027316). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [0.0](/filings/0001437749-25-034499.md) | [0.0 d](/filings/0001437749-26-009387.md) | [27.0](/filings/0001437749-26-016748.md) | [0.0](/filings/0001437749-26-027316.md) | [1.0](/filings/0001437749-25-034499.md) | [0.0 d](/filings/0001437749-26-009387.md) | [0.0](/filings/0001437749-26-016748.md) | [0.0](/filings/0001437749-26-027316.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | [(10800.0%)](/filings/0001437749-26-016748.md) | not reported | [(342200.0%)](/filings/0001437749-25-034499.md) | not reported | not reported | not reported | | Net margin | % | not reported | not reported | [(9603.7%)](/filings/0001437749-26-027316.md) | not reported | [(443600.0%)](/filings/0001437749-25-034499.md) | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | not reported | [(0.10)](/filings/0001437749-25-016898.md) | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $k | [(2,936) d](/filings/0001437749-25-034499.md) | [(2,254) d](/filings/0001437749-26-009387.md) | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [2.8](/filings/0001437749-23-008737.md) | [0.0](/filings/0001437749-24-006849.md) | [0.7](/filings/0001437749-25-010250.md) | [0.0](/filings/0001437749-26-009387.md) | [0.0](/filings/0001437749-26-009387.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1276.3%)](/filings/0001437749-23-008737.md) | not reported | [(2594.3%)](/filings/0001437749-25-010250.md) | not reported | [(48157.1%)](/filings/0001437749-26-009387.md) | | Net margin | % | [(1245.5%)](/filings/0001437749-23-008737.md) | not reported | [(2826.0%)](/filings/0001437749-25-010250.md) | not reported | [(51035.7%)](/filings/0001437749-26-009387.md) | | Diluted EPS | $ per share | [(5.86)](/filings/0001437749-23-008737.md) | [5.72](/filings/0001437749-24-006849.md) | [(1.29)](/filings/0001437749-24-006849.md) | not reported | not reported | | Free cash flow | $m | [(31.8)](/filings/0001437749-23-008737.md) | [(28.7)](/filings/0001437749-24-006849.md) | [(17.6)](/filings/0001437749-25-010250.md) | [(12.7)](/filings/0001437749-26-009387.md) | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tlph/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Rosalind Advisors, Inc.](/funds/1622627.md) | 2026-06-30 | $5.3m | 5,169,501 | | Added +1,815,585 | | [AIGH Capital Management LLC](/funds/1835943.md) | 2026-06-30 | $4.7m | 4,601,502 | | Reduced −60,000 | | [Rock Springs Capital Management LP](/funds/1595725.md) | 2026-06-30 | $3.7m | 3,589,186 | | Unchanged | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $3.6m | 3,492,519 | | Unchanged | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $3.6m | 3,492,519 | | Unchanged | | [Bleichroeder LP](/funds/1781002.md) | 2026-06-30 | $1.3m | 1,307,787 | | Unchanged | | [CANTOR FITZGERALD, L. P.](/funds/1024896.md) | 2026-06-30 | $914.1k | 887,481 | | Unchanged | | [CANTOR FITZGERALD, L. P.](/funds/1024896.md) | 2026-06-30 | $914.1k | 887,481 | | Unchanged | | [Dauntless Investment Group, LLC](/funds/2044285.md) | 2026-06-30 | $768.4k | 746,051 | | Added +310,817 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $722.9k | 701,877 | | Added +260,266 | ## Recent filings [All 961 filings](/companies/tlph/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-12 | 16:11 ET | [10-Q](/filings/0001437749-26-027316.md) | Quarterly report, period 2026-06-30 | 0001437749-26-027316 | | 2026-08-12 | 16:08 ET | [8-K](/filings/0001437749-26-027311.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-027311 | | 2026-06-23 | 16:27 ET | [8-K](/filings/0001437749-26-021446.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001437749-26-021446 | | 2026-05-13 | 16:31 ET | [10-Q](/filings/0001437749-26-016748.md) | Quarterly report, period 2026-03-31 | 0001437749-26-016748 | | 2026-05-13 | 16:10 ET | [8-K](/filings/0001437749-26-016724.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-016724 | | 2026-04-29 | 16:31 ET | [DEF 14A](/filings/0001437749-26-013895.md) | Proxy statement, period 2026-06-22 | 0001437749-26-013895 | | 2026-03-23 | 16:05 ET | [10-K](/filings/0001437749-26-009387.md) | Annual report, period 2025-12-31 | 0001437749-26-009387 | | 2026-03-23 | 08:35 ET | [8-K](/filings/0001437749-26-009299.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-009299 | | 2026-03-16 | 08:30 ET | [8-K](/filings/0001437749-26-008318.md) | 3.02 Unregistered sale of equity | 0001437749-26-008318 | | 2026-03-13 | 16:05 ET | [8-K](/filings/0001437749-26-008217.md) | 3.01 Delisting notice | 0001437749-26-008217 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-009387.md), filed Mar 23, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/22ef1e7b-384c-4e10-b8db-45b5125c67fa) ## About the filer - CIK: 1427925 - Tickers: TLPH - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.